Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
Objective: Multiple myeloma (MM) has a better survival outcome because of the development of drugs. However, equivalent outcomes cannot be expected from the same drug. Therefore, how the treatment schedule is managed is important. We analyzed VMP (bortezomib, melphalan, and prednisolone) data to det...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2019-05-01
|
| Series: | Turkish Journal of Hematology |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-78045 |
| _version_ | 1828021608660336640 |
|---|---|
| author | Su-Hee Cho Ho-jin Shin Ki Sun Jung Do Young Kim |
| author_facet | Su-Hee Cho Ho-jin Shin Ki Sun Jung Do Young Kim |
| author_sort | Su-Hee Cho |
| collection | DOAJ |
| description | Objective: Multiple myeloma (MM) has a better survival outcome because of the development of drugs. However, equivalent outcomes cannot be expected from the same drug. Therefore, how the treatment schedule is managed is important. We analyzed VMP (bortezomib, melphalan, and prednisolone) data to determine an effective treatment strategy. Materials and Methods: We collected the data of 59 patients who were newly diagnosed with MM from January 2012 to April 2017 using electronic medical records. We analyzed baseline characteristics, responses, dose reductions, and survival. Results: The overall response rate was 86.5% [complete response (CR): 32.2%, very good partial response (VGPR): 37.3%]. The median progression-free survival was 33.6 months and the 5-year overall survival rate was 70%. There were significant better progression-free survival outcomes between CR and non-CR for each of the 4 cycles. Of the four patients who achieved CR after the first cycle, none have had disease progression as of yet. We divided patients into two groups according to the median dose (52.1 mg/m2) and we found no differences between the high-dose and low-dose groups. About 78% of patients completed 9-cycle schedules and 84% patients experienced dose reduction, mostly for reasons of non-hematologic toxicities. Conclusion: Active dose reduction helped to continue treatment and it increased the opportunity to be exposed to drugs. In the end, it resulted in improved outcome. |
| first_indexed | 2024-04-10T11:55:44Z |
| format | Article |
| id | doaj.art-4614d1631f2b4a91a2b139ec11579ce4 |
| institution | Directory Open Access Journal |
| issn | 1308-5263 |
| language | English |
| last_indexed | 2024-04-10T11:55:44Z |
| publishDate | 2019-05-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkish Journal of Hematology |
| spelling | doaj.art-4614d1631f2b4a91a2b139ec11579ce42023-02-15T16:16:48ZengGalenos Publishing HouseTurkish Journal of Hematology1308-52632019-05-0136210611110.4274/tjh.galenos.2019.2019.0306TJH-78045Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) TreatmentSu-Hee Cho0Ho-jin Shin1Ki Sun Jung2Do Young Kim3Pusan National University Yangsan Hospital, Clinic of Hematology-Oncology, Busan, KoreaPusan National University Yangsan Hospital, Clinic of Hematology-Oncology, Busan, KoreaPusan National University Yangsan Hospital, Clinic of Hematology-Oncology, Busan, KoreaPusan National University Yangsan Hospital, Clinic of Hematology-Oncology, Busan, KoreaObjective: Multiple myeloma (MM) has a better survival outcome because of the development of drugs. However, equivalent outcomes cannot be expected from the same drug. Therefore, how the treatment schedule is managed is important. We analyzed VMP (bortezomib, melphalan, and prednisolone) data to determine an effective treatment strategy. Materials and Methods: We collected the data of 59 patients who were newly diagnosed with MM from January 2012 to April 2017 using electronic medical records. We analyzed baseline characteristics, responses, dose reductions, and survival. Results: The overall response rate was 86.5% [complete response (CR): 32.2%, very good partial response (VGPR): 37.3%]. The median progression-free survival was 33.6 months and the 5-year overall survival rate was 70%. There were significant better progression-free survival outcomes between CR and non-CR for each of the 4 cycles. Of the four patients who achieved CR after the first cycle, none have had disease progression as of yet. We divided patients into two groups according to the median dose (52.1 mg/m2) and we found no differences between the high-dose and low-dose groups. About 78% of patients completed 9-cycle schedules and 84% patients experienced dose reduction, mostly for reasons of non-hematologic toxicities. Conclusion: Active dose reduction helped to continue treatment and it increased the opportunity to be exposed to drugs. In the end, it resulted in improved outcome.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-78045multiple myelomabortezomibmelphalanprednisolone |
| spellingShingle | Su-Hee Cho Ho-jin Shin Ki Sun Jung Do Young Kim Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment Turkish Journal of Hematology multiple myeloma bortezomib melphalan prednisolone |
| title | Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment |
| title_full | Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment |
| title_fullStr | Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment |
| title_full_unstemmed | Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment |
| title_short | Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment |
| title_sort | dose adjustment helps obtain better outcomes in multiple myeloma patients with bortezomib melphalan and prednisolone vmp treatment |
| topic | multiple myeloma bortezomib melphalan prednisolone |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-78045 |
| work_keys_str_mv | AT suheecho doseadjustmenthelpsobtainbetteroutcomesinmultiplemyelomapatientswithbortezomibmelphalanandprednisolonevmptreatment AT hojinshin doseadjustmenthelpsobtainbetteroutcomesinmultiplemyelomapatientswithbortezomibmelphalanandprednisolonevmptreatment AT kisunjung doseadjustmenthelpsobtainbetteroutcomesinmultiplemyelomapatientswithbortezomibmelphalanandprednisolonevmptreatment AT doyoungkim doseadjustmenthelpsobtainbetteroutcomesinmultiplemyelomapatientswithbortezomibmelphalanandprednisolonevmptreatment |